anti-CD30 immunotoxin | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

20,387 results for “anti-CD30 immunotoxin”

Trials

View all 10400 →

Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease

12 participants · First posted Mar 21, 2008

Not yet recruiting

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

42 participants · First posted Sep 19, 2022

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

26 participants · First posted Feb 10, 2017

Drugs

View all 4041 →

immunotoxin

anti-CD30 apatamers

Investigational

D2C7 immunotoxin

Organizations

View all 78 →

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

News

View all 5868 →

Newcastle University Researchers Identify Novel CD30-Targeting Combination Therapy to Overcome Immune Checkpoint Blockade Resistance in Melanoma

WuXi Biologics Partners with Virogen to Advance First-in-Class Anti-CD3 Immunotoxin VG712 Toward Commercial Manufacturing

Merck Assumes Full Control of MK-8690 Anti-CD30 Ligand Antibody for Inflammatory Bowel Disease

Page 1 of 2039